Boehringer/WellPoint Outcomes Research To Inform Pradaxa Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
The study in non-valvular atrial fibrillation patients is the first project to launch under a five-year research agreement between Boehringer Ingelheim and WellPoint.
You may also be interested in...
Boehringer And Anthem Put Stiolto Duo To Real World Test In COPD
US noninferiority study mainly of Anthem beneficiaries aims to show if COPD patients are being overtreated with LABA/LAMA/ICS triple combos when a LABA/LAMA duo would do.
BI’s Pradaxa Gets Mixed Reviews In Postmarketing Studies
Two observational studies of Medicare patients reach different conclusions on Pradaxa bleeding rates, but FDA says risk/benefit profile of drug has not changed.
Boehringer Avoids Pradaxa Trial, Board Chair Deposition With $650 Mil. Settlement
Settlement expected to resolve approximately 4,000 Pradaxa personal injury claims.